Bafna Pharmaceuticals Ltd (BAFNAPH) — shareholding pattern, promoter holding, financials and share price
About Bafna Pharmaceuticals Ltd (BAFNAPH)
Bafna Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BAFNAPH and on the BSE under scrip code 532989. Its ISIN is INE878I01022.
Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations [1]
Bafna Pharmaceuticals Limited is engaged in manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. It operates multiple manufacturing units with WHO GMP and ISO 9000 certifications.
The company holds Export House status from the Government of India and has expanded into regulated markets of Europe, exporting products to Srilanka, Ukraine, and Ghana.
Listed peers in Pharmaceuticals: Zim Laboratories Ltd, Haleos Labs Limited, Jenburkt Pharmaceuticals Ltd, Transchem Ltd, Albert David Ltd, Aptus Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹207.55 a share on 10 Jul 2026, Bafna Pharmaceuticals Ltd (BAFNAPH) was valued at a price-to-earnings ratio of 44.23x against an industry P/E of 36.41x and a price-to-book of 5.79x on a book value of ₹35.85 per share as of Mar 2025. Solomo computes return on equity of 13.09% and return on capital employed of 12.95% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 44.23x
- Industry P/E
- 36.41x
- P/B
- 5.79x
- EPS (TTM)
- ₹4.69
- Book value / share
- ₹35.85
- ROE
- 13.09%
- ROCE
- 12.95%
- ROA
- 7.25%
- Debt / equity
- 0.33x
- Dividend yield
- 0%
- EBITDA margin
- 13.74%
- 52-week range
- ₹77.01 – ₹234.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2020In the year ended Mar 2020, Bafna Pharmaceuticals Ltd (BAFNAPH) reported revenue of ₹42 crore, net profit of ₹-24 crore and earnings per share of ₹-104.54. That compares with revenue of ₹44 crore and net profit of ₹-18 crore in Mar 2019. Figures are consolidated, as filed with the exchanges.
In the quarter ended Sep 2019, revenue was ₹11.57 crore and net profit ₹-0.59 crore (consolidated).
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 85 | 65 | 46 | 44 | 42 |
| Net profit (₹ cr) | -15 | -19 | -17 | -18 | -24 |
| EPS (₹) | -7.52 | -10.23 | -7.08 | -7.98 | -104.54 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.99% | 27.99% | 19.65% | -2.66% |
| Profit growth | - | - | -7.32% | -33.19% |
| Stock price CAGR | 22% | 6% | 34% | 149% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 75% of Bafna Pharmaceuticals Ltd (BAFNAPH) (unchanged from the previous quarter), foreign institutional investors (FII) hold 9.34%. Market capitalisation was ₹491 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: M7 GLOBAL FUND PCC-AERION 3.21%, M7 GLOBAL FUND PCC - CELL DEWCAP FUND 3.12%, ZEAL GLOBAL OPPORTUNITIES FUND 3.01%, ALPANA MUNDRA 2.73%, MONARCH NETWORTH FINSERVE PRIVATE LIMITED 1.35%, GUTTIKONDA VARA LAKSHMI 1.29%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 75% | - | 9.34% | - | 25% |
| Mar 2026 | 75% | - | 9.34% | - | 25% |
| Dec 2025 | 75% | - | 9.34% | - | 25% |
| Sep 2025 | 75% | - | 9.34% | - | 25% |
| Jun 2025 | 75% | - | 9.34% | - | 25% |
| Mar 2025 | 75% | - | 8.53% | - | 25% |
| Dec 2024 | 88.3% | - | - | - | 11.7% |
| Sep 2024 | 88.3% | - | - | - | 11.7% |